NCT02782208 - Lipolytic Effects of GH in Hypopituitary Patients in Vivo | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 10, 2016

Primary Completion Date

December 22, 2016

Study Completion Date

December 22, 2016

Conditions

HypopituitarismInsulin ResistanceEndocrine System DiseasesGlucose Metabolism DisordersMetabolic DiseasesPituitary DiseasesBrain Diseases

Interventions

DRUG

Acipimox

Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.

DRUG

Placebo

Placebo is administered 4 times previous to and during the investigation day.

DRUG

GH substitution

GH substitution as usually

OTHER

GH pause

GH substitution pause two days prior to the experimental day

Trial Locations (1)

University Hospital of Aarhus, Aarhus

All Listed Sponsors

lead

University of Aarhus

OTHER